VXRT

Insider Trades

Name	Value	Action	Price	Current Price
Watson W. MarkDirector $6.5k10k shares BuyMay 22, 2026 $0.653 --
Watson W. MarkDirector $2.0k5k shares BuyNov 17, 2025 $0.407 --
Heron Elaine JDirector $9.1k23.2k shares BuyNov 17, 2025 $0.393 --
Heron Elaine JDirector $6.8k16.8k shares BuyNov 17, 2025 $0.405 --
Watson W. MarkDirector $6.2k15k shares BuyNov 17, 2025 $0.41 --
Finney KevinDirector $19k50k shares BuyAug 15, 2025 $0.37 --

News

globenewswire.comVaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meetingglobenewswire.comJun 16

globenewswire.comVaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forumglobenewswire.comJun 15

globenewswire.comVaxart to Participate in BTIG Infectious Disease Day 2026globenewswire.comJun 9

globenewswire.comVaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAYglobenewswire.comJun 8

globenewswire.comVaxart Files Definitive Proxy Statement and Mails Letter to Shareholdersglobenewswire.comJun 1

Trade VXRT

About Vaxart, Inc.

Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.

CEO: Steven Lo
IPO Date: Dec 11, 1981

Market Data

Open: $0.5621
High: $0.5999
Low: $0.55
Volume: 123.2K
Avg Volume: 412.2K
52W High: $0.84
52W Low: $0.26

Valuation

Market Cap: $133M
Enterprise Value: $90M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $7.6M
Revenue: $237M
Net Income: $16M
Cash: $54M
Debt: $9.0M

Events

EarningsMay 7

EPS est. -0.21 · actual 0.02